Edwards Lifesciences Corporation (NYSE:EW) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Edwards Lifesciences Corporation (NYSE:EW) have been assigned an average recommendation of “Moderate Buy” from the twenty-seven brokerages that are presently covering the firm, MarketBeat reports. Nine equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have given a strong buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $96.1364.

Several research analysts have recently commented on the stock. TD Cowen upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a research note on Friday, January 9th. Piper Sandler reiterated an “overweight” rating and issued a $100.00 price objective (up from $98.00) on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Canaccord Genuity Group set a $87.00 target price on shares of Edwards Lifesciences and gave the stock a “hold” rating in a research report on Wednesday, December 17th. The Goldman Sachs Group restated a “buy” rating and set a $95.00 target price (down from $108.00) on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Finally, Royal Bank Of Canada boosted their price target on Edwards Lifesciences from $95.00 to $100.00 and gave the stock an “outperform” rating in a research report on Friday, December 5th.

Insider Activity at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 11,340 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $85.93, for a total value of $974,446.20. Following the completion of the sale, the vice president directly owned 21,266 shares in the company, valued at approximately $1,827,387.38. The trade was a 34.78% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Daniel J. Lippis sold 1,019 shares of the company’s stock in a transaction that occurred on Friday, January 9th. The stock was sold at an average price of $85.70, for a total value of $87,328.30. Following the sale, the vice president directly owned 22,002 shares of the company’s stock, valued at $1,885,571.40. The trade was a 4.43% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 71,444 shares of company stock valued at $6,035,269. Corporate insiders own 0.34% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. JPL Wealth Management LLC bought a new stake in Edwards Lifesciences during the third quarter valued at about $25,000. MV Capital Management Inc. bought a new position in shares of Edwards Lifesciences in the fourth quarter worth about $26,000. Kemnay Advisory Services Inc. bought a new position in shares of Edwards Lifesciences in the fourth quarter worth about $27,000. True Wealth Design LLC lifted its position in shares of Edwards Lifesciences by 251.5% during the 3rd quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock worth $28,000 after purchasing an additional 259 shares during the last quarter. Finally, Kohmann Bosshard Financial Services LLC acquired a new position in shares of Edwards Lifesciences during the 4th quarter worth about $28,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Up 3.2%

Shares of Edwards Lifesciences stock opened at $84.21 on Tuesday. The firm has a market cap of $48.91 billion, a price-to-earnings ratio of 46.02, a P/E/G ratio of 2.13 and a beta of 0.93. The stock has a 50-day simple moving average of $82.51 and a 200-day simple moving average of $81.49. Edwards Lifesciences has a 52-week low of $65.94 and a 52-week high of $87.89. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.72 and a quick ratio of 3.09.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Tuesday, February 10th. The medical research company reported $0.58 EPS for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). The firm had revenue of $1.57 billion during the quarter, compared to analyst estimates of $1.54 billion. Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The company’s quarterly revenue was up 13.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.59 EPS. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, equities research analysts expect that Edwards Lifesciences will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.